Reading CRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRMD free→Reading CRMD? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track CRMD free→QuarterlyIQ Insights · CRMD
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Regulation FD Disclosure On June 8, 2026, CorMedix, Inc. (the “Company”) issued a press release on the decision by the United States Court of Appeals for the Federal Circuit in Melinta Therapeutics, LLC, et al. v. Nexus Pharmaceuticals, Inc. , which affirmed the district court’s judgment that Nexus Pharmaceuticals Inc.’s generic minocycline product infringed two of the Company’s patents and rejected Nexus’s invalidity challenge. A copy of the press release is furnished as Exhibit 99.1, attach…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.